CJC-1295 vs Ipamorelin
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context.
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context.
PubMed paper counts, ClinicalTrials.gov listings, and regulatory context—aggregated from public databases.
GH release
A long-acting GHRH analog that extends GH pulses—often stacked with ipamorelin.
CJC-1295 mimics growth hormone-releasing hormone. The DAC version binds albumin for a longer half-life. Intended effects: lean mass support, sleep quality, and recovery. Prescription analogs exist in different forms; gra…
GH release
A selective growth-hormone secretagogue peptide—stimulates GH with less appetite spike than older GHRPs.
Ipamorelin binds ghrelin receptors and triggers pituitary GH release without strongly raising cortisol or prolactin. Clinics pair it with CJC-1295 for anti-aging and body-composition goals. Not FDA-approved for OTC use; …
Both are categorized under GH release in our directory—here is how they differ in name, use, and label context. CJC-1295 is categorized as GH release; Ipamorelin as GH release. CJC-1295: A long-acting GHRH analog that extends GH pulses—often stacked with ipamorelin. Ipamorelin: A selective growth-hormone secretagogue peptide—stimulates GH with less appetite spike than older GHRPs.
No. They are different molecules with distinct names on labels and in research databases. Always match the full INCI or drug name—not a nickname on the front of the package.
Neither page is medical or anti-doping advice. Research peptides discussed in fitness communities may be prohibited in tested sport or unavailable as OTC supplements. Verify WADA lists and talk to a clinician.